

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **LANSEN PHARMACEUTICAL HOLDINGS LIMITED**

**朗生醫藥控股有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock code: 503)**

### **DISPOSAL OF STARRY SHARES**

Reference is made to the circular (the “**Circular**”) of the Company dated 24 June 2020 in relation to the mandate to dispose shares (the “**Starry Shares**”) of Zhejiang Starry Pharmaceutical Co., Ltd. (“**Starry**”) held by the subsidiary of the Company and the announcement of the Company dated 9 April 2020 in relation to the Sixth Share Reduction Plans. Capitalised terms used herein shall have the same meanings as those defined in the Circular unless the context otherwise requires.

At the Extraordinary General Meeting on 13 July 2020, the Shareholders granted the New Starry Disposal Mandate to the Directors for the disposal of all or part of Starry Shares (and any future bonus issue entitlement) for a 12-month period commencing 13 July 2020.

During the period from 14 July 2020 to 17 July 2020, the Company disposed on-market of an aggregate of 2,349,505 Starry Shares at the average price of RMB78.97 per Starry Share pursuant to the New Starry Disposal Mandate and the Sixth Share Reduction Plans for an gross sale proceeds of approximately RMB185.55 million and, after deducting transaction costs and related tax, expected to be approximately RMB174.68 million (equivalent to approximately US\$24.67 million). The Group is expected to recognise a net gain of approximately US\$21.93 million which is calculated on the basis of the difference between the net disposal proceeds and the amount of investment costs of disposed Starry Shares. The above-mentioned US\$ amounts are converted based on the approximate exchange rate of US\$1=RMB7.0795, and the actual exchange rate used in conversion may be different.

The Company has disposed of an aggregate of 2,349,505 Starry Shares from the date of the New Starry Disposal Mandate have been granted.

After this disposal of Starry Shares, 7,052,855 Starry Shares are owned by the Group, which value will be subject to market price fluctuations.

By Order of the Board  
**Lansen Pharmaceutical Holdings Limited**  
**Wu Zhen Tao**  
*Chairman*

Hong Kong, 17 July 2020

*As at the date of this announcement, the executive managing Director is Mr. Chen Li; the non-executive Directors are Mr. Wu Zhen Tao, Mr. Stephen Burnau Hunt and Ms. Liu Xuezi; the independent non-executive Directors are Mr. Chan Kee Huen, Michael, Mr. Fritz Heinrich Horlacher and Mr. Yeung Tak Bun, Allen.*

*For the purpose of this announcement, unless otherwise defined, conversions of RMB into US\$ are based on the approximate exchange rate of US\$1=RMB7.0795 for the purposes of illustration only. No representation is made that any amount in US\$ and RMB could have been or could be converted at the above rate or any other rates.*